China will account for nearly half the world’s hepatitis B drug sales by 2024, industry analysts predict.
Research and consulting firm GlobalData said it expected the country to remain the largest market over the next decade.
It said sales would rise from just under $923 million in 2014 to over $1.4 billion by 2024, representing a compound annual growth rate (CAGR) of 4.4%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze